Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bergstrand

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Social Problems|September 9, 1979
Victim-blaming and the "looping" effect of social policy: the cause of physician maldistribution and underserved rural communitiesC R Bergstrand
British Journal of Clinical Pharmacology|March 1, 1991
Influence of acid secretory status on absorption of omeprazole from enteric coated granulesT Andersson, R Bergstrand, C Cederberg
European Journal of Clinical Investigation|October 1, 1979
Glucose tolerance, plasma insulin and alpha-lipoproteins in young male myocardial infarction survivors compared with controls matched on serum cholesterol concentrationR Bergstrand, O Wiklung, G Holm, et al.
Journal of Chronic Diseases|January 1, 1983
Bias due to non-participation and heterogenous sub-groups in population surveysR Bergstrand, A Vedin, C Wilhelmsson, et al.
Acta Medica Scandinavica|January 1, 1980
Skin cholesterol and DNA in young patients with myocardial infarctionT Björnheden, O Wiklund, R Bergstrand, et al.
Journal of Chronic Diseases|January 1, 1983
Characteristics of males with myocardial infarction below age 40R Bergstrand, A Vedin, C Wilhelmsson, et al.
Cardiovascular Drugs and Therapy|November 1, 1996
Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervalsB Darpö, O Almgren, R Bergstrand, et al.
Journal of Clinical Pharmacology|February 1, 1990
Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided dosesP Lücker, G Moore, I Wieselgren, et al.
Pharmaceutical Research|January 1, 1993
Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosingA Sandberg, B Abrahamsson, A Svenheden, et al.
Journal of Clinical Pharmacology|February 1, 1990
Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjectsI Wieselgren, P Lundborg, A Sandberg, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Social Problems|September 9, 1979
Victim-blaming and the "looping" effect of social policy: the cause of physician maldistribution and underserved rural communitiesC R Bergstrand
British Journal of Clinical Pharmacology|March 1, 1991
Influence of acid secretory status on absorption of omeprazole from enteric coated granulesT Andersson, R Bergstrand, C Cederberg
European Journal of Clinical Investigation|October 1, 1979
Glucose tolerance, plasma insulin and alpha-lipoproteins in young male myocardial infarction survivors compared with controls matched on serum cholesterol concentrationR Bergstrand, O Wiklung, G Holm, et al.
Journal of Chronic Diseases|January 1, 1983
Bias due to non-participation and heterogenous sub-groups in population surveysR Bergstrand, A Vedin, C Wilhelmsson, et al.
Acta Medica Scandinavica|January 1, 1980
Skin cholesterol and DNA in young patients with myocardial infarctionT Björnheden, O Wiklund, R Bergstrand, et al.
Journal of Chronic Diseases|January 1, 1983
Characteristics of males with myocardial infarction below age 40R Bergstrand, A Vedin, C Wilhelmsson, et al.
Cardiovascular Drugs and Therapy|November 1, 1996
Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervalsB Darpö, O Almgren, R Bergstrand, et al.
Journal of Clinical Pharmacology|February 1, 1990
Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided dosesP Lücker, G Moore, I Wieselgren, et al.
Pharmaceutical Research|January 1, 1993
Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosingA Sandberg, B Abrahamsson, A Svenheden, et al.
Journal of Clinical Pharmacology|February 1, 1990
Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjectsI Wieselgren, P Lundborg, A Sandberg, et al.
Pageof 4